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Abstract 
Title: Coronary artery disease in females. 
Objective:  
1. To find the various modes of presentation and clinical profile of coronary artery disease in 
females 
2. To study the associated risk factopors 
Design: Prospective cross sectional study. 
Place: Coimbatore Medical College Hospital, Coimbatore, Tertiary Care Hospital. 
Period of study: September 2010 to June 2011 
Inclusion criteria:  1. Patients above 40 years 
2. Hypertension 
   3. Diabete mellitus 
   4. Dyslipidemia 
Exclusion criteria:  1. Congenital heart disease 
   2. Rheumatic heart disease 
   3. Structural heart disease 
   4. Electrical abnormalities 
Subjects: 100 female patients admitted with symptoms, signs and ECG changes suggestive of CAD with 
biochemical markers taken as cases. 
Results: In this study, 33% were among age group between 60 - 70 years. Coronary artery disease 
mortality among women gradually increases with age and increase in the risk of coronary artery disease 
is related to a higher incidence of hypertension, diabetes, obesity, and dyslipidemia. 
Conclusion: 
1. The most common presentation is chest pain. 
2. Waist-hip ratio associated with obesity and overweight increases the risk of myocardial 
infarction in female populations. 
3. Most common presentation is STEMI. 
4. Systemic hypertension, diabetes mellitus also associated with increased trisk of MI 
Keywords: Coronary artery disesae, females, systemic hypertension, diabetes mellitus, obesity. 
11. INTRODUCTION
Coronary heart disease has been defined as “impairment of heart function due to 
inadequate blood flow to the heart compared to its needs, caused by obstructive changes in 
the coronary circulation to the heart”.
Coronary heart disease is assuming serious dimension in developing countries. It is expected 
to be the single most important cause of death in India by the year 2015.
Coronary artery disease is the leading cause of death among women, regardless of race or 
ethnicity and causing the deaths of 1 in 3 women than from stroke, lung cancer, chronic 
obstructive lung disease, and breast cancer combined.
Women with coronary artery disease present differently than men, have different 
pathophysiologies and risks profiles and are often significantly older and thus often have 
poorer outcomes.
Experts in industrialized societies have long recognized that the first presentation with 
coronary heart disease occurs approximately 10 years later among women than men, most 
commonly after menopause.
Although coronary artery disease in general manifests earlier in less well-developed 
countries, the approximate 8 to 10 years age gap in time of onset between men and women is 
universal.
Despite this delay in onset, mortality from coronary heart disease is increasing more rapidly 
among women than men from both developed and developing world.
22. AIM OF STUDY
1. This study is to find the various modes of presentation and clinical profile of coronary 
artery disease in females.
2. To study the associated risk factors, there is an urgent need to recognize all these 
conditions so as to reduce the burden associated with it in terms of increased morbidity 
and mortality.
33. REVIEW OF LITERATURE
DEFINITION:
Coronary heart disease has been defined as “impairment of heart function due to inadequate 
blood flow to the heart compared to its needs, caused by obstructive changes in the coronary 
circulation to the heart”.
Depending on the rate of development and ultimate severity of the arterial narrowing(S) and 
the myocardial response, four ischemic syndromes may results.
1. Angina pectoris, of which there are three variants, the most threatening being unstable 
angina.
2. Myocardial infarction, the most important form, in which there can be substantial 
myocardial damage.
3. Chronic ischemic heart disease with CHF.
4. Sudden cardiac death.
Many women die every year from cardiovascular disease than from any other cause, yet 
women worry more about breast cancer than heart disease. Women with heart disease may 
present differently than men, have unique underlying pathophysiologies, and have distinctive 
risk benefit profiles with commonly accepted therapies(1).
Heart disease is far more age dependent in women than in men; women with cardiovascular 
disease are older and have more co morbidities. This fact, in turn, make diagnostic and treatment 
procedures more problematic in women. In addition, many effective pharmacological strategies 
are underutilized, and there is a lack of gender-specific date on numerous therapies. The fact that 
4heart disease is on the decline in men but not women highlights our failure to treat this large 
segment of the population optimally. 
The aetiology of atherothrombotic  cardiovascular disease is multi-factorial, and several ‘risk 
factors’ are recognized to predispose an individual to develop the disease. 
These cardiovascular risk factors, which were initially characterized in the Framingham 
Heart Study, include: age, family history of premature cardiovascular disease, smoking, 
hypertension, hyperlipidaemia, diabetes, obesity and sedentary lifestyle.
Although a family history of cardiovascular disease is a recognized risk factor, it is 
important to emphasize that cardiovascular disease is polygenic and numerous genetic 
abnormalities have been implicated in the development of the final common disease state. 
Furthermore, expression of disease is often closely linked to environmental risk factors such as 
smoking, diet and physical inactivity.
In addition, the disease does not present until middle age, or later, in most cases. Clearly, 
therefore, the ‘burden of disease’ in a population is strongly associated with the prevalence of 
recognized risk factors within that population. Incidence and prevalence rates for cardiovascular 
diseases depend to a large extent 
5Figure 3.1 Atheromatous Plaque
on the age profile of the population, socio-economic, dietary and other lifestyle patterns; 
although other influences, including genetic differences influenced by ethnicity, are also 
important. 
RISK FACTORS FOR CORONARY HEART DISEASE IN WOMEN AND THEIR 
MODIFICATION
Diabetes Mellitus and Metabolic Syndrome
       Diabetes is associated with a greater incremental risk in women, completely eliminating the 
“female advantage.”  The American Heart Association awards double weight to diabetes in 
women(2) when calculating CHD risk, similar to the weight given a systolic blood pressure of 
173 mm Hg or above or cholesterol level of 316 mg/dl or above. More than in men, diabetes 
6dramatically increases the mortality of myocardial infarction in women. Type 2 diabetes(3) is 
associated with obesity, abdominal body fat distribution, hypertension, atherogenic dyslipidemia, 
and insulin resistance, all of which have been associated with higher CHD risk.
      This complex of abnormalities, termed “metabolic syndrome,” alters hepatic metabolism, 
lipoprotein levels, and circulating insulin levels. More so than in men, obesity and body fat 
distribution appear to be independent coronary artery disease risk factor in women(4). Diabetes is 
also linked with endothelial dysfunction and a variety of platelet abnormalities(5). Data from the 
Diabetes Control and Complications Trail suggest that intensive diabetes therapy reduces 
cardiovascular complications in men and women younger than 40 years.
Hypertension
      More than 25 million American women have high blood pressure, and cardiovascular risk 
related to hypertension(6) rises steeply with age in females. Further, although women have fewer 
cardiovascular events, the population risk attributable to hypertension is higher for women(7) than 
men because of the increased incidence with age and the longevity of women. 
Nonpharmacological interventions effectively decrease blood pressure in women, including a 
low-salt diet, physical activity, and weight loss. However, compliance with such changes is low 
(~10 percent) and blood pressure increases again when physical activity decreases or weight is 
regained. 
        Most trails have shown equal efficacy of blood pressure lowering to prevent cardiovascular 
events in men and women. The seventh Joint National Committee on Prevention, Detection, 
Evaluation, and Treatment of High Blood Pressure includes a single set of guidelines for both 
7men and women, stating that “large, long-term clinical trials of antihypertensive treatment have 
not demonstrated clinically significant gender(8) differences in blood pressure response and 
outcomes.” Although it is clear that hypertension in women should be treated as aggressively as 
in men, it is possible that the optimal choice of antihypertensive agent may differ.
      The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack 
Trial(ALLHAT) demonstrated superiority of diuretic therapy in the prospecified female cohort, 
as in the trial as a whole. The Second Australian National Blood Pressure Study Group found 
that angiotensin-converting enzyme (ACE) inhibitor therapy decreased cardiovascular endpoints 
relative to hydrochlorothiazide in men but not in women. The numbers of women included in 
trials are often too small to draw conclusions.
Smoking
        Tobacco contributes to 17 percent of all female deaths in the United States and results in 
more deaths from CHD and stroke than any other cause. The combination of accelerated 
atherosclerosis and propensity to vascular thrombosis induced by cigarette smoking is 
responsible for a six-to nine-fold increased risk of myocardial infarction among female smokers 
compared with nonsmokers. There is a similar increase in stroke risk. The combination of 
cigarette smoking and oral contraceptive use appears to be particularly potent at increasing the 
risk of arterial thrombosis.
       Cigarettes have an antiestrogenic effect and induce an unfavorable lipid profile, leading 
women to lose their “natural” protection against atherosclerotic vascular disease. Currently 
available methods to assist with quitting may be less effective in women, perhaps because of a 
8greater behavioral component and less nicotine addiction in women smokers. Environmental 
exposure to tobacco smoke increases the risk of cardiovascular disease in women, and 
assessment of environmental exposure is an important part of risk assessment.
Lipids
      The average lipid profile women are affected by hormonal status and changes throughout 
life. Young women have lower low-density lipoprotein (LDL)(9) cholesterol levels and higher 
high-density lipoprotein (HDL)(10) cholesterol levels than men of the same age. As women age, 
LDL cholesterol increases, HDL cholesterol decreases, and the risk of CHD climbs. Elevated 
total cholesterol and LDL levels are only weakly associated with CHD in women and only in 
women 65 years old or younger. Instead, HDL cholesterol is closely and inversely associated 
with CHD(11) risk. 
       
Figure 3.2 Risk in CAD
9          Triglycerides(12) are an independent predictor of CHD, particularly in older women. 
Lipoprotein(a), a composite of LDL, apolipoprotein B-100, and apolipoprotein(a), is also 
associated with higher cardiac risk in women. Initial modification of a high-risk lipoprotein 
profile is generally accomplished by the same life-style changes and medications in men and 
women, although dietary interventions may be less effective in women.
   Multiple trials have demonstrated efficacy of 3-hydroxy-3-methylglutaryl coenzyme A (HMG 
CoA) reductase inhibitors(13), or statins in both primary and secondary prevention of coronary 
events and death in women with both elevated and normal cholesterol, supporting the persistent 
theory that there are benefits of these agents independent of LDL-lowering effects.
    Women have generally not been included in trails of other classes of lipid-lowering agents, 
such as the bile acid sequestrant cholestyramine and the fibrate gemfibrozil. 
    In addition, there are no data from large trails on the efficacy of lipid-lowering agents targeted 
more specifically at altering the HDL and triglyceride lipid subfractions, which appear more 
important in women. It seems reasonable to apply strategies shown to be successful in men, 
recognizing that optimal care of women with dyslipidemia may eventually be different from that 
of men(14).
Estrogen
       The presence of estrogen in the premenopausal female population, the obvious protection 
this group enjoys against cardiovascular events, and documentation of estrogen receptors in 
cardiomyocytes and vascular tissues in both men and women led tremendous enthusiasm for use 
of postmenopausal hormone replacement therapy as a preventive measure against atherosclerotic 
heart disease. This enthusiasm was bolstered by multiple observational studies suggesting 
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improved longevity and decreased cardiac events in postmenopausal women receiving hormone 
replacement therapy as well as mechanistic data supporting biological plausibility(15).
     Multiple randomized controlled trails in the past 3 years have refuted this hypothesis and 
provided strong evidence of an increase in cardiovascular risk particularly in the first year after 
beginning therapy, combined with increased risk of breast cancer, thromboembolic disease, and 
stroke, resulting in a withdrawal of prior recommendations. 
      In the Women’s Health Initiative Study, use of estrogen alone, without a progestin, neither 
caused nor prevented cardiac events, although it did increase the risk of stroke and decrease the 
risk of hip fracture. Other studies documenting progression of atherosclerosis during hormone 
replacement therapy have confirmed the lack of benefit. Hormone replacement therapy has no 
place in prevention of heart disease in women at present.
      Many questions about estrogen remain unanswered. Would alternative formulations of either 
estrogen or progesterone be of benefit? Does starting therapy immediately at menopause 
eliminate risk? Can genotype predict the risk-benefit profile of estrogen therapy? In addition, if 
the estrogen hypothesis is indeed a fallacy, what does afford the protection in the premenopausal 
female population? Several candidates have been suggested, although none have substantial 
scientific support: lower iron levels and higher oxytocin levels, for example. Estrogen therapy is 
associated with impressive changes in so many risk factors, including lower LDL, higher HDL, 
improved glucose tolerance, and reductions in weight and waist circumference, that an 
understanding of the mechanism of increased risk is likely to revolutionize yet again our 
understanding of the atherosclerotic process.
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Diet and Obesity
       Excess caloric intake and obesity are a growing epidemic worldwide, and more than one-
third of American women are classified as obese. The Nurses’ Health Study revealed a sevenfold 
higher cardiovascular mortality in the heaviest women, and Framingham Offspring study 
demonstrated a dramatic rise in risk factors for cardiovascular disease at body mass indices 
above 20. 
      Obesity is associated with elevated-reactive protein (CRP), particularly in women. The 
combination of obesity and diabetes appears particularly deadly in women, as does the pattern of 
fat distribution. Abdominal fat accumulation is an important predictor of type 2 diabetes 
mellitus, hypertriglyceridemia, hypertension, and CHD(16) . Among women, a waist-to-hip ratio 
greater than 0.88 is predictive of a substantially increased risk of cardiovascular events, as is a 
waist circumference of more than 38 inches(17).
Physical Activity
    Physical Activity(18) is more prevalent among women than men. There is a strong inverse 
association between physical activity and coronary events in women. Physical activity also has a 
salutary effect on other cardiovascular risk factors, including hypertension, obesity, and diabetes 
mellitus. 
      The effect of regular exercise to increase HDL cholesterol and include weight loss may be 
less in women than in men. Significant barriers to regular exercise exist for American women, 
particularly older women. Caregiving duties, low energy, and lack of peers seen exercising are 
cited as impeding women’s compliance with exercise recommendations.
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Inflammation
     The close relationship between inflammation and cardiovascular risk is discussed in depth 
elsewhere. Baseline CRP levels predict future cardiovascular risk in healthy women, particularly 
those metabolic syndrome. Although we currently lack clinical trial evidence in support of CRP 
as a target of therapy, the ability of statins to reduce CRP is associated with benefit in lipid-
lowering trials and ability of oral estrogen to raise CRP is associated with harm.
Psychosocial Factors
     The interaction of psychosocial and behavioral factors and heart disease is complex and has 
not been rigorously studied. Several cardiovascular risk factors are related to behavior (obesity, 
smoking, exercise), yet modification may be more difficult for women than for men, with 
caregiving roles often blamed for this failure. 
      Perceived stress and lack of situational control have been found to increase CHD risk in both 
genders. Social networks and support influence CHD outcome both independently and through 
the likelihood of compliance with therapeutic strategies and their impact may be greater in 
women, who are more likely to live alone. Although depression increases cardiac risk in both 
women and men, a causal relationship is unclear, as is the impact of treatment.
Emerging Risk Factors
      Many newer markers of increased cardiovascular risk apply equally to men and women, 
including abnormal endothelial reactivity, increased pulse pressure (thought to be a surrogate for 
increased vascular stiffness), factor V Leiden mutation, hyperhomocysteinemia, and elevated 
fibrinogen. 
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     Estrogen increases fibrinogen levels, explaining the increased risk of vascular thrombosis 
associated with exogenous estrogen therapy. Although several members of the coagulation and 
fibrinolysis cascade have been proposed as possible risk factors, most recently through genetic 
polymorphisms, current data support a role for these factors as modifiers of risk rather than 
causal. 
     Whether targeting any of these emerging risk factors for intervention produces a reduction in 
cardiovascular events is unknown.
ACUTE CORONARY SYNDROMES
      The term “acute coronary syndrome” is used to describe a spectrum of conditions having in 
common; varying degrees of rupture of vulnerable atherosclerotic plaques is the coronary 
arteries.
      It includes the clinical entities of unstable Angina, non-ST Elevation Myocardial Infarction 
and ST Elevation Myocardial Infarction.
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Figure 3.3 Acute coronary syndrome
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Table 3.1: CORONARY ARTERY PATHOLOGY(19)
Syndrome Pathology
1. Stable Angina >75% stenoses
2. Unstable Angina Plaque rupture with mural thrombus, often 
thromboembolic
3. Myocardial Infarction Plaque rupture, complete thrombosis
4. Sudden death Severe multi vessel disease, often Plaque 
rupture, often thrombus or thromboembolic 
Figure 3.4 Acute syndrome
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Potential outcomes of reversible and irreversible ischaemic injury
Figure 3.5 Potential outcomes of ischemia
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Causes of nonatherothrombotic coronary artery disease
Arteritis:
 Infection:
Bacterial.
Fungal.
Viral.
Rickettsial.
Spirochetal.
 Immunological
Immune complex-mediated:lupus vasculitis, hepatitis B microscopic polyarteritis.
Direct antibody attack-mediated:Kawasaki (antiendothelial antibodies)
ANCA associated (mediated):Wegener’s granulomatosis.
Cell-medicated:best known is allograft organ rejection.
Hypersensitivity reaction:drugs.
 Unknown:
Polyarteritis nodosa (classic)
Giant cell arteritis.
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Takayasu’s arteritis.
Embolism 
 Infectious endocarditis.
 Nonbacterial thrombotic endocarditis (NBTE).
 Parasitic disorders.
 Vegetations on catheters or fragment of catheter: iatrogenic material.
 Tumors:
Myxoma
Paradoxical; embolus.
Foreign bodies, including gas.
Occlusion of the coronary arterial orifice
 Thrombus from stalky endocarditic excrescence.
 Papillary fibroelastoma: papillary tumor of the leaflet.
 Surgical material:
Felt pads, which can also be embolic.
Suture material gripping the coronary artery in relation to arterioplastic operations 
or bypass
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Dissection
 Spontaneous
 Marfan
 Hypertension.
Miscellaneous
 Congenital coronary anomalies:
Arteriovenous malformation.
Anomalous origin of coronary arteries.
 Fibromuscular dysplasia/hyperplasia.
 Perivascular/vascular fibrosis in hypertrophic cardiomyopathy
 Endocrine and metabolic disorders:
Diabetes, hypothyroidism.
Homocysteinemia, mucopolysaccharidoses.
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CLINICAL FEATURES
STEMI(20)
1) Chest pain
Site Substernal
Nature Pressing, Squeezing, Strangling, Constricting, ‘a band across the 
chest’, ‘a weight in the centre of the chest’. The patient cannot 
pinpoint the site of pain.
Radiation To both the shoulders, epigastrium, back, neck, jaw, teeth. Anginal 
pain can be radiate in all directions, as mentioned above, but more 
commonly radiates to the left shoulder and ulnar aspect of the left 
arm.
Duration 5-15minutes
Aggravating Factors Exertion, emotion, after a heavy meal, or exposure to cold.
Relieving Factors Rest, nitrates.
Table 3.2
2) Often accompanied by Weakness, Sweating, Nausea, Vomiting, anxiety and Sense of 
impending doom.
3) May present as 
 Sudden onset of breathlessness
 With or without pain
 Loss of consciousness
 A confusional state
 A sensation of profound weakness
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 The appearance of arrhythmia
 Evidence of peripheral embolism
 Merely an unexplained drop in arterial pressure.
Physical signs include
1. Elevated BP, low because of cardiogenic shock
2. Basal crepitation
3. S3, S4
4. Systolic murmur of MR
5. Soft S1
6. Paradoxic S2
7. Pallor
8. Sweating, restless, in agony due to  pain and tossing in the bed in an attempt to get relief
9. Pulse – rapid or slow ,regular or irregular
Tachycardia – AWMI
Bradycardia – IWMI
10. Pulmonary edema.
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Investigations
Blood Investigations
1. Leucocytosis with polymorphonuclear reaction
2. High ESR
3. Elevated CRP
ECG changes may be normal initially, hence serial ECGs must be taken
1. ST Elevation and T wave inversion(21)
2. T wave inversion in opposite leads
3. Q wave on the ECG
Cardiac Markers
1. Cardiac – Specific Troponin T and I(22)
2. Creatinine  Phosphokinase(23)
3. LDH1
4. AST
5. Myoglobin.
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Enzyme levels in acute MI
Figure 3.6 Enzyme levels according to time
Radionuclide imaging techniques
     Myocardial perfusion imaging with 201T1 or 99m TC – sestamibi, which are distributed in 
proportion to myocardial blood flow and concentrated by viable myocardial, reveal a ‘cold spot’ 
(defect).
Figure 3.7 Block shows in Infarcted area and 18 sliced CT angiogram
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99m TC- labeled red blood cells frequently demonstrates wall motion disorders and reduction in 
the ventricular ejection fraction.
Myocardial infarction can be detected accurately with high resolution cardiac MRI using 
(gadolinium) a technique referred to as late enhancement.
Figure 3.8 Shows in 64 slice computed tomography in coronary angiogram
a) CPK-MB This cardiac isoenzyme starts rising within 4-6 his after development of acute MI, 
peaks during the 2nd  day (4 fold risk) and disappears in 2-3days
b) ASI Starts rising on the 1st day, peaks in 2-3days (3 fold rise) and disappears by 3rd day.
c) LDH1 Starts rising by second day, peaks around 3-4days (3 fold rise) and disappears in 10 
days.
d) Troponin T Cardiac Troponin T is a regulatory contractile protein hot normally found in blood. 
Its detection in the circulation has been shown to be a sensitive and specific marker 
for myocardial cell damage.
Troponin T and I reach a reliable diagnostic level in plasma by 12-16 hrs, maximal 
activity by 24-32 hrs, returns to normal in 10-12 days.
Troponin I :0-0.4 ng/ml
Cardiac troponin are detected in the serum by using monoclonal antibodies. These 
antibodies have negligible cross reactivity to skeletal muscle. Cardiac troponin I 
and T start to rise within 3-4 hours after myocardial infarction and remain raised for 
4-10 days.
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Chest X-ray
Signs of heart failure or pulmonary edema.
Cardiac Imaging
Echo 
     Abnormalities of wall motion on two-dimensional echocardiography are almost universally 
present. LV function estimation is assessed. Echo may also identify the presence of RV 
infarction, ventricular aneurysm, pericardial effusion, LV thrombus.
Doppler echo detects – VSD, MR
Management
1. Asses the vital signs
2. Establish an IV line
3. Connect the patient to a cardiac monitor
4. Measure O2 saturation in breathless patients.
1) Start O2 using a nasal canula ( 4-6l/min)
Especially in pulmonary edema or oxygen saturation <90% continue for 4-6 hrs.
2) Aspirin (325mg) is given to the patient, to be chewed and swallowed continue 150-
325mg / day indefinitely.
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3) Inj.Morphine – for Analgesia 5 mg IV stat and 2 mg IV can be repeated every 10 minutes 
till adequate analgesia is achieved (Maximum dose of 16mg)
Caution: in inferior wall MI as it may precipitate heart blocks Inj.Pethidine 50-100 mg IV 
with Inj.Phenargan 12.5-25 mg IV is an alternative analgesia.
4) a) Sublingual nitroglycerine
 0.4 mg can be repeated every 15 minutes maximum of 3 tablets
 If the pain is not relieved with adequate sublingual Nitroglycerine tablets and 
morphine injection, start nitroglycerine drip.
b) Nitroglycerine drip
Indications
 For 24-489 hours in case of persistent angina
 Large AMI
 MI with CCF or hypertension .
10 µgram/min to increase to 200 µgram/min for pain relief.Titrate dose to 
pain relief with monitoring of blood pressure.
CI
Hypotension- SBP less than 90mmHZ change over to oral nitrates when pain 
subsides.
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5) Thrombolysis with streptokinase ( to decide and start at the earliest, ideally within 30 
minutes of chest pain/entry to emergency department)
If there are no contraindications and the BT, CT, PT, APTT and platelet count are 
normal.
 Best response it used within 6 hrs of onset
 Can be used upto 12-24 hrs. 
Indications 
 Typical chest pain
 ECG/enzyme evidence
 <12 hrs from onset of pain
 Age less than 75 yrs.
Major contraindication for streptokinase(24)
 Stroke within the previous 12 months
 Severe hypertension BP >180/110mmHg
 Bleeding disorders and patient on anticoagulants.
 Active peptic ulcer
 Surgery within the previous one month
 Recent aggressive cardiac resuscitation
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 Previous treatment with SK
Use of SK
 1.5 million units dissolved in 100 ml of NS to run in one hour
 750000 units in the first 20 minutes as IV infusion
 750000 units in the next 40 minutes as IV infusion
 Give 100 mg of hydrocortisone and 25 mg pheniramine meleate IV before giving SK 
to present minor allergic reaction
 If BP falls, give volume expanders like saline.
6) If pain persists after thrombolysis consider urgent PTCA or CABG.
7) Inj.Heparin
 To prevent clot formation and embolization in cases of large MI/AI
 LV thrombus – stabilize the clot
 Following thrombolysis/PTCA/CABG.
UFH
 gives 6 hrs after the SK to maintain APTT Around 1.5 to 2 times the control for 5-
7days
 5000 IU IVstat followed by 1000 U/hour IV alternatively
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LMWH
 Given 5-7 days Enoxaparin 1 mg/kg/BD
 No need to monitor APTT but it is expensive
8) Beta blockers
Indications
1. All patients with 12 hrs of MI with no major contraindication to this drug
2. Patients with recurring or ongoing chest pain
3. Arrhythmias such as AF/VF
 Metoprolol 5mg IV stat and repeat every 5 minutes if needed till 15 mgs.
 Use oral beta-blockers indefinitely’
 Metoprolol 50mg orally BD.
Use with caution
1. IWMI
2. SBP < 95mm/Hg
3. HR < 55/min
4. Severe LVD
5. Heart blocks
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6. Severe COPD/Asthma
9) ACE inhibitors
If cardiac failure / LVD/
 Enalapril 5-20mg
 Ramipril 2.5-20mg
Avoid in hypotension /renal failure/ hyperkalemia.
10) Calcium channel blockers
 Used only when beta-blockers are contraindicated and there is ongoing chest pain.
 To control ventricular rate in AF
 Avoid in CCF and LVD
 Diltiazem – bolus 0.25 mg/kg IV over 2-5 min for arrhythmias
 Infusion dose is 5-15mg / hour. 250mg in 250 ml = 1ml. infusion rate 5-
15ml/hour or microdrops/min or Diltizem PO 30-60mg 8th hourly.
11) Amiodarone
 For atrial and ventricular arrhythmia.
 Bolus – 150mg in 20ml 5% D over 5-15 minutes.
 Infusion – Inj.Amiodarone 1amp = 3ml = 150mg
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 6amp in 500ml of 5% D slow loading dose 1mg/min.
Supportive Treatment
1. Reassurance
2. Complete Bed rest for 12-24 hrs if no complications
3. Movements of legs in bed and deep breathing exercises
4. Avoid straining or valsalva for any reason including defecation and passing urine
5. Laxative to be given to avoid straining during defaecation
6. Toilet facilities near bedside
7. Sedatives like Diazepam 5-10mg or alprazolam 0.5mg should be given at night and a 
calm and quiet atmosphere to be maintained
8. Diet – It patient in stable soft diet, small frequent feeds are started after 6 hrs of MI.
9. Treat Hyperlipidemia
 If LDL >100mg/dl or
 HDL <35mg/dl.
10. Specific treatment of complication
 Severe hypotension
 Pulmonary edema
 Arrhythmias     Should be treated
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Refer for cardiac pacing if there is
1. Asystolic
2. Symptomatic bradycardia
3. BBB or bifascicular blocks or complete heart block. 
While waiting for cardiac pacing the following drugs can be tried
 Inj.Atropine 1mg IV, total 3 doses
 Inj.Deriphylline 1 amp
 Inj.Isoprenaline 2mg in 500ml NS/5% D.
NSTEM1 AND UNSTABLE ANGINA ARE CLOSELY RELATED IN PATHOGENESIS 
AND CLINICAL PRESENTATION.
UNSTABLE ANGINA
Symptoms
1. Angina at rest
2. Recent onset severe angina
3. Progressing severity of angina
4. Post infarction angina
ECG
1. May show ST depression and
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2. T wave inversion
3. NO ST elevation /Q wave
4. Normal cardiac enzymes
Treatment 
1) Aspirin 325mg oral stat and daily. If not tolerated, ticlodipine 250mg BD monitor for 
neutropenia.
2) Heparin – unfractionated
1000 IU/hr, as an infusion with monitoring APTT (Or)
LMW Heparin – given for 5 days
1) Enoxaparin 1mg/kg SC BD
2) Dalteparin 100 IU/kg SC BD
3) Nandopanin 50 IU/kg SC BD
4) Reviparine 3500-6300 U SC BD
5) Fondaparinux - OD
3) Beta blockers
 Atenolol 50-100mg
 Metoprolol 50-100mg 12th hrly
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 Watch for BP fall and bradycardia
4) Nitrates 
 NTG IV starting from 10-30µg/mt  upto 200-400 µg/min. Titrate the dose to 
relieve pain 
 Watch for hypotension <90mmHg
 In hypertensives do not lower below 120mmHg systolic
 If Pt has mild pain, oral or S/L glyceryl trinitrate 0.5mg every 3 minutes till the 
pain subsides C maximum 3mg in (hr).
5) Calcium channel blockers
 Used only if beta blockers are contra indicated, 
 Avoid short acting drugs like nifedipine
 Diltiazem 30 to 60 mg TID can be given.
6) Treat Associated Aggravating factors like anemia, stress, fever, tachyarrhythmia
 Detect and treat risk factors like DM, SHT, Lipid abnormalities
 Advice to stop smoking
 If pain subsides, Treadmill test on drugs is indicated, after the patient in stable.
 Depending upon the outcome revascularistion can be planned for high risk 
patients.
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 Refractory Angina – Refer for emergency PTCA/CABG(24) .
Complications
Figure 3.9 Complications
A, Anterior myocardial rupture in an acute infarct (arrow). B, Rupture of the ventricular septum 
(arrow). C, Complete rupture of a necrotic papillary muscle. D, Fibrinous pericarditis, showing a 
dark, roughened epicardial surface overlying an acute infarct. E, Early expansion of anteroapical 
infarct with wall thinning (arrow) and mural thrombus. F, Large apical left ventricular aneurysm. 
The left ventricle is on the right in this apical four-chamber view of the heart. 
1. Arrhythmias
2. Heart failure
3. Cardiogenic shock
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4. Sudden death
5. Infarction of papillary muscle of mitral value
6. Rupture of Interventricular septum leading to VSD
7. Thrombosis in LV causing cerebral embolism
8. Rupture of ventricle into pericardial sac  causing cardiac tamponade
9. Deep vein thrombosis is legs causing pulmonary embolism
10. Pericarditis during massive infarction
11. Aneurysm of ventricle with thrombosis and thrombo embolic phenomenon
12. Dressler’s syndrome.
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Table 3.3: Evaluation and interventions in relation to different components of a multifactorial 
rehabilitation program
Evaluation Intervention
Patient assessment Medical history
Physical examination
Compose patient care program.
Nutritional 
counseling
Obtain estimate of daily food intake
Assess eating habits
Prescribe dietary modifications.
Individualize eating plan.
Educate and counsel patient (and 
family).
Smoking cessation Document smoking status
Determine readiness to change
Provide formal smoking cessation 
program
Update status at each visit
Weight 
management
Measure weight height, and 
circumference.
Calculate BMI
In patients with BMI>25 establish 
reasonable short-term and long-term 
weight goals.
Develop a combined diet, exercise and 
behavioral program.
Exercise training Obtain an exercise test Develop a documented individualized 
exercise prescription for aerobic 
resistance training.
Psychosocial 
management
Use interview and/or standardized 
measurement tools to identify 
psychosocial distress
Offer individual education and 
counseling.
Develop supportive rehabilitation 
environment to enhance social support
Cooperate with appropriate mental 
health specialist.
Discharge therapy Evaluate relevant long-term therapy with 
aspirin, beta blockers, and ACE 
inhibitors. 
Monitor dose adjustments and side 
effects (ECG, kidney function)
Lipid management Obtain fasting measures of total 
cholesterol, HDL, LDL and TG.
Repeat lipid profiles 4-6 weeks after 
hospitalization and 2 months after 
changes in therapy.
Provide nutritional counseling and add 
drug treatment until:
LDL <100 mg/dl (2.8 mmol/l),
HDL >35 mg/dl (1.0 mmol/l),
TG <200 mg/dl (2.5 mmol/l).
Hypertension and 
diabetes 
management
Measure of resting BP on at least 2 visits.
Identify diabetic subjects.
Obtain fasting plasma glucose in all 
patients and HbA l c in diabetic patients 
to monitor therapy.
Continue assessment and optimize 
treatment until:BP <140/90 mmHg 
[18.7/12 kPa] or BP <130/85 mmHg 
[17.3/11.3 kPa] (diabetics).
Continue monitoring and optimize 
diet, exercise, and oral hypoglycemic 
agents or insulin until near 
normalization of glycemic control 
with  HbA l c <7.0%.
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The DASH Diet:
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4. MATERIALS AND METHODS
PLACE OF THE STUDY
 The study was conducted at Government Coimbatore Medical College hospital, 
Coimbatore (Tertiary Care Centre).
PERIOD OF STUDY
 September 2010 to June 2011
DESIGN 
 Prospective cross sectional study.
METHODOLOGY
 Hundred female patients admitted with symptoms and signs and ECG changes suggestive 
of CAD with Biochemical markers taken as cases.
INCLUSION CRITERIA
1. Patients above 40 years
2. Hypertension
3. Diabetes mellitus
4. Dyslipidemia 
EXCLUSION CRITERIA
1. Congenital Heart disease.
2. Rheumatic Heart disease.
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3. Structural Heart disease.
4. Electrical abnormalities.
 Admitted 100 female patients were examined and detailed history was taken about the 
patients menstrual history, sedentary habits, Dietary habits, Smoking habits, h/o Alcohol 
intake, h/o OCP intake, Family h/o and systemic hypertension and Type 2 DM and others 
risk factor analysis was made.
 Baseline investigations like complete blood count, urine R/E, renal function test, ECG, 
Chest X-ray, Blood pressure monitoring was done in all study subjects.
 Hypertension was considered by documented history of hypertension/medication or with 
BP >140/90 mmHg, during the present visit.
 Diabetes mellitus was considered by documented history. Fasting blood Sugar and 
Postprandial Blood Sugar values were evaluated.
1. FBS- 126 & Above
    Taken as criteria for DM.
2. PPBS-160 & Above
 Clinical Symptoms like chest pain, Nausea, Vomiting, Dysponea, Syncope Radiation of 
the pain were all taken into account.
 Signs like hypotension, hypertension, raised JVP, S3, S4, Lung Crepitations, where were 
all looked for.
 Total cholesterol, LDL, HDL, Triglycerides levels identified and taken into the study.
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 Patients were grouped into four categories according to their age as 40-50 yrs, 50-60 yrs, 
60-70 yrs, above 70 yrs.
 Body mass Index was calculated by wt(kg)/ht(m2) in all patients. Waist/Hip ratio 
calculated in all patients. 
Killip Score was assigned according to the clinical presentation.
Killip Classification
Class Features
I No heart failures
II Mild to moderate heart failure (S3; rales 
no more than half way to the back)
III Severe heart failure (Pulmonary edema)
IV Cardiogenic shock 
Table 4.1
 Electrocardiogram was performed in all study subjects
 Echocardiogram was performed in all study subjects
 Troponin study was done in NSTEMI and unstable angina patients.
Types of ECG Abnormalities Recorded
 ST Elevation MI
 Non ST Elevation MI
 Unstable Angina  
42
ECG PATTERNS
 Extensive anterior Wall MI – L1, avL and Precordial leads.
 Anteroseptal wall MI –V1 to V4.
 Anterolateral wall MI –L1, avL, V4, V5, V6.
 Apical wall MI –V5, V6.
 Inferior wall MI –LII, LIII, avF.
 Interolateral wall MI –LII, LIII avF, V5, V6.
 RVMI –V1 and V4 R
 Postenior wall MI –Right V1-V3 and especially V2 – respect the universe charge.
BMI
CLASSIFICATION BMI
Underweight <18.50
Normal range 18.50 – 24.99
Overweight ≥ 25.00
Pre – obese 25.00 – 29.00
Obese Class I
           Class II
           Class III
30.00 – 34.99
35.00 – 39.99
≥ 40.00
WAIST HIP RATIO
More than 0.85 considered as risk for metabolic complications.
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LIPID PROFILES
Total cholesterol (mg%)
LDL cholesterol (mg%)
<100 Optimal
100-129 Near optimal/above
160-180 High
≥ 190 Very high.
HDL (mg%)
<40 Low
≥ 60 Borderline high
TGL (mg%)
<150 N
150-199 Borderline high
200-499 High
≥ 500 Very high.
<200 Desirable
200-239 Borderline high
>240 High
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STATISTICAL METHODS EMPLOYED
Following statistical methods were employed in the present study.
1. Chi-square test
2. Independent samples‘t’ test
3. One-Way ANOVA.
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5. RESULTS AND ANALYSIS
1. AGE WISE DISTRIBUTION
100 patients were studied in this study grouped into four category.
 Between 40-50 yrs
 Between 50-60 yrs
 Between 60-70 yrs
 Above 70 yrs
Age Frequency (No of Patients)
Between 40-50 yrs 17
Between 50-60 yrs 24
Between 60-70 yrs 33
Above 70 yrs 26
Total 100 patients
                                                    
2. BMI (wt(kg)/ht(m2))
Observations
In this study
 Healthy – 26 patients
 Overweight – 51 patients
 Obese – 23 patients
Age wise distribution of BMI
Age Healthy Overweight Obese Total
Between 40-50 yrs 5 9 3 17
Between 50-60 yrs 6 13 5 27
Between 60-70 yrs 10 14 9 33
Above 70 yrs 5 15 6 26
Total 26 51 23 100
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3. WAIST HIP RATIO
 0.85 considered as significant
 81% (81 out of 100 patients presented with >0.85 WHR.
 19% (19 out of 100 patients) presented with <0.85 WHR.
4. MENSTRUATION 
In this study 7% (7 out of 100) patients were menstruating women.
5. SEDENTARY HABITS
In this study 89% (89 out of 100) patients reported to have sedentary habits.
Age Sedentary Habits Total
No Yes
Between 40-50 yrs 4 3 17
Between 50-60 yrs 1 23 24
Between 60-70 yrs 4 29 33
Above 70 yrs 2 24 26
Total 11 89 100
BMI * SED
Crosstab
6 20 26
23.1% 76.9% 100.0%
54.5% 22.5% 26.0%
4 47 51
7.8% 92.2% 100.0%
36.4% 52.8% 51.0%
1 22 23
4.3% 95.7% 100.0%
9.1% 24.7% 23.0%
11 89 100
11.0% 89.0% 100.0%
100.0% 100.0% 100.0%
Count
% within BMI
% within SED
Count
% within BMI
% within SED
Count
% within BMI
% within SED
Count
% within BMI
% within SED
Healthy
Over weight
Obese
BMI
Total
No Yes
SED
Total
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BMI and Sedentary Habits
BMI Sedentary Habits Total
No Yes
Healthy 6 20 26
Overweight 4 47 51
Obese 1 22 23
Total 11 89 100
Chest pain and Sedentary Habits
Chest Pain Sedentary Habits Total
No Yes
No 1 11 12
Yes 10 78 88
Total 11 89 100
Age * Chest Pain
Crosstab
3 14 17
17.6% 82.4% 100.0%
25.0% 15.9% 17.0%
3 21 24
12.5% 87.5% 100.0%
25.0% 23.9% 24.0%
4 29 33
12.1% 87.9% 100.0%
33.3% 33.0% 33.0%
2 24 26
7.7% 92.3% 100.0%
16.7% 27.3% 26.0%
12 88 100
12.0% 88.0% 100.0%
100.0% 100.0% 100.0%
Count
% within Age
% within Chest Pain
Count
% within Age
% within Chest Pain
Count
% within Age
% within Chest Pain
Count
% within Age
% within Chest Pain
Count
% within Age
% within Chest Pain
Between 40 - 50 years
Between 50 - 60 years
Between 60 -70 years
Above 70 years
Age
Total
No Yes
Chest Pain
Total
Chi-Square Tests
5.432a 2 .066
4.944 2 .084
4.509 1 .034
100
Pearson Chi-Square
Likelihood Ratio
Linear-by-Linear
Association
N of Valid Cases
Value df
Asymp. Sig.
(2-sided)
2 cells (33.3%) have expected count less than 5. The
minimum expected count is 2.53.
a. 
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6. No smoking habits patients were studied. 2% (2out of 100 patients) reported to have 
habits of alcohol intake.
7. History
     Oral contraception intake was questioned and found that 40% of the patient gave the 
history in this study (40 out of 100 patients).
8. Clinical Symptoms
 Chest pain is the most common presenting symptom.
 88% (88 out of the 100 patients) presented with chest pains.
Clinical Symptoms
0
10
20
30
40
50
60
70
80
90
100
Chest Pain Nausea Vomiting Syncope Radiation Dyspnoea Others
Chi-Square Tests
.976a 3 .807
.978 3 .807
.869 1 .351
100
Pearson Chi-Square
Likelihood Ratio
Linear-by-Linear
Association
N of Valid Cases
Value df
Asymp. Sig.
(2-sided)
4 cells (50.0%) have expected count less than 5. The
minimum expected count is 2.04.
a. 
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Symptoms
 Chest pain – 88%
 Nausea – 81%
 Vomiting – 62%
 Syncope – 50%
 Radiation – 45%
 Dyspnoea – 31%
 Other ( Palpitation, epigastric pain) – 29%
Clinical Symptoms
9. Clinical signs
 Lung basal Crepitation is the most common presentation of clinical sign.
Chest Pain
Nausea
Vomiting
Syncope
Radiation
Dyspnoea
Others
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Signs
No of Cases
(Total = 100 patients)
JVP 23
S3 16
S4 24
Crepitations 45
Wheeze 8
Hypotension 10
Clinical Signs
Signs
 JVP – 23%
 S3 – 16%
0
10
20
30
40
50
60
JVP S3 S4 Crepitation Wheeze Hypotension
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 S4 – 24%
 Crepitation  – 45%
 Wheeze – 8%
 Hypotension – 16%
Clinical Signs
JVP
S3
S4
Crepitation
Wheeze
Hypotension
10. Type 2DM
In this study 
 45% (45 out of 100 patients) presented with elevated fasting blood sugar level.
 50% (50 out of 100 patients) presented with elevated post prandial glucose level.
Age and Fasting Blood Sugar
Age Fasting Blood Sugar Total
Normal Abnormal
Between 40-50 yrs 8 9 17
Between 50-60 yrs 17 7 24
Between 60-70 yrs 16 17 33
Above 70 yrs 14 12 26
Total 55 45 100
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Age and Postprandial Blood Sugar
Age Postprandial Blood 
Sugar
Total
Normal Abnormal
Between 40-50 yrs 6 11 17
Between 50-60 yrs 14 10 24
Between 60-70 yrs 18 15 33
Above 70 yrs 12 14 26
Total 50 50 100
Chest pain and Fasting Blood Sugar
Chest
(yes/no)
Fasting Blood Sugar Total
Normal Abnormal
No 6 6 12
Yes 49 39 88
Total 55 45 100
Chest Pain * Fasting Blood Sugar (Diabetes Mellitus)
Crosstab
6 6 12
50.0% 50.0% 100.0%
10.9% 13.3% 12.0%
49 39 88
55.7% 44.3% 100.0%
89.1% 86.7% 88.0%
55 45 100
55.0% 45.0% 100.0%
100.0% 100.0% 100.0%
Count
% within Chest Pain
% within Fasting Blood
Sugar (Diabetes Mellitus)
Count
% within Chest Pain
% within Fasting Blood
Sugar (Diabetes Mellitus)
Count
% within Chest Pain
% within Fasting Blood
Sugar (Diabetes Mellitus)
No
Yes
Chest
Pain
Total
Normal Abnormal
Fasting Blood Sugar
(Diabetes Mellitus)
Total
Chi-Square Tests
.138b 1 .711
.004 1 .951
.137 1 .711
.764 .472
.136 1 .712
100
Pearson Chi-Square
Continuity Correction a
Likelihood Ratio
Fisher's Exact Test
Linear-by-Linear
Association
N of Valid Cases
Value df
Asymp. Sig.
(2-sided)
Exact Sig.
(2-sided)
Exact Sig.
(1-sided)
Computed only for a 2x2 tablea. 
0 cells (.0%) have expected count less than 5. The minimum expected count is 5.
40.
b. 
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Chest pain and Postprandial Blood Sugar
Chest
(yes/no)
Postprandial Blood 
Sugar
Total
Normal Abnormal
No 7 5 12
Yes 43 45 88
Total 50 50 100
Chest Pain * Post Prandial
11. Systemic Hypertension
In this study 25% (25 out of 100) patients presented with High blood pressure.
Crosstab
7 5 12
58.3% 41.7% 100.0%
14.0% 10.0% 12.0%
43 45 88
48.9% 51.1% 100.0%
86.0% 90.0% 88.0%
50 50 100
50.0% 50.0% 100.0%
100.0% 100.0% 100.0%
Count
% within Chest Pain
% within Post Prandial
Count
% within Chest Pain
% within Post Prandial
Count
% within Chest Pain
% within Post Prandial
No
Yes
Chest
Pain
Total
Normal Abnormal
Post Prandial
Total
Chi-Square Tests
.379b 1 .538
.095 1 .758
.380 1 .537
.760 .380
.375 1 .540
100
Pearson Chi-Square
Continuity Correctiona
Likelihood Ratio
Fisher's Exact Test
Linear-by-Linear
Association
N of Valid Cases
Value df
Asymp. Sig.
(2-sided)
Exact Sig.
(2-sided)
Exact Sig.
(1-sided)
Computed only for a 2x2 tablea. 
0 cells (.0%) have expected count less than 5. The minimum expected count is 6.
00.
b. 
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12. Lipid abnormalities
 37% (37 out of 100 patients) found to have high levels of cholesterol.
 57% (57 out of 100 patients) found to have HDL <50 m/dl.
 40% (40 out of 100 patients) found to have high LDL cholesterol >130 mg/dl.
 59% (59 out of 100 patients) found to have high levels of triglycerides.
0
10
20
30
40
50
60
70
Increase Total
Cholesterol
Increase LDL
Cholestrol
Increase
Triglycerides
Increase HDL
Cholesterol
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BMI * Total Cholesterol
BMI * Triglycerides
Crosstab
19 7 26
73.1% 26.9% 100.0%
30.2% 18.9% 26.0%
31 20 51
60.8% 39.2% 100.0%
49.2% 54.1% 51.0%
13 10 23
56.5% 43.5% 100.0%
20.6% 27.0% 23.0%
63 37 100
63.0% 37.0% 100.0%
100.0% 100.0% 100.0%
Count
% within BMI
% within Total
Cholesterol
Count
% within BMI
% within Total
Cholesterol
Count
% within BMI
% within Total
Cholesterol
Count
% within BMI
% within Total
Cholesterol
Healthy
Over weight
Obese
BMI
Total
Normal Abnormal
Total Cholesterol
Total
Chi-Square Tests
1.654a 2 .437
1.699 2 .428
1.467 1 .226
100
Pearson Chi-Square
Likelihood Ratio
Linear-by-Linear
Association
N of Valid Cases
Value df
Asymp. Sig.
(2-sided)
0 cells (.0%) have expected count less than 5. The
minimum expected count is 8.51.
a. 
Crosstab
11 15 26
42.3% 57.7% 100.0%
26.8% 25.4% 26.0%
22 29 51
43.1% 56.9% 100.0%
53.7% 49.2% 51.0%
8 15 23
34.8% 65.2% 100.0%
19.5% 25.4% 23.0%
41 59 100
41.0% 59.0% 100.0%
100.0% 100.0% 100.0%
Count
% within BMI
% within Triglycerides
Count
% within BMI
% within Triglycerides
Count
% within BMI
% within Triglycerides
Count
% within BMI
% within Triglycerides
Healthy
Over weight
Obese
BMI
Total
Normal Abnormal
Triglycerides
Total
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13. ECG was performed in all patients
Types of Abnormalities
 ST Elevation MI – 80%
 Non ST Elevation MI – 10%
 Unstable Angina – 10%
Types of MI No of Patients
ASMI 32
AWMI 20
IWMI 16
IWMI + RVMI 9
IWMI + RVMI + PWMI 2
ALMI 1
Total 80
Chi-Square Tests
.482a 2 .786
.489 2 .783
.262 1 .609
100
Pearson Chi-Square
Likelihood Ratio
Linear-by-Linear
Association
N of Valid Cases
Value df
Asymp. Sig.
(2-sided)
0 cells (.0%) have expected count less than 5. The
minimum expected count is 9.43.
a. 
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ECG Features of CAD
ECG Features of CAD
0
20
40
60
80
100
STEMI NSTEMI/UA NSTEMI UA
STEMI
NSTEMI/UA
NSTEMI
UA
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ECG Features of STEMI
ECG Features of STEMI
ASMI
AWMI
IWMI
IWMI+RVMI
IWMI+RVMI+PWMI
ALMI
0
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ASMI AWMI IWMI IWMI+RVMI IWMI+RVMI+PWMI ALMI
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14. Troponin
 Cardiac markers study done in NSTEMI patients.
 50% (10 out of 20 patients) found to have specific cardiac markers.
15. Echo was performed in all study groups.
16. CRP was performed in all study groups and 71% found to have positive (Elevated) CRP 
(71 out of 100 patients).
17.
Age Thrombolysed Total
No Yes
Between 40-50 yrs 11 6 17
Between 50-60 yrs 18 6 24
Between 60-70 yrs 25 8 33
Above 70 yrs 25 1 26
Total 79 21 100
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6. DISCUSSION
      Coronary artery diseases are major causes of mortality and disease in the Indian subcontinent 
with more than 25% deaths. It has been predicted that these diseases will increase rapidly in 
India and this country will be host to more than half the cases of heart diseases in the world 
within the next 15 yrs.
     Women constitute 48% of the total population in India. However due to inadequate 
perception and attention, coronary heart disease remains a formidable health problem in women.
 Women represent 60% of those over the age of 65 years in the United States (US) and 
more women than men have died of cardiovascular disease (CVD) since 1984.
 Among women, the lifetime risk of death from CAD is more than 10-fold greater than 
that from breast cancer
 Since 1960, life expectancy in India has increased by 20 years to 61 years of age.
 In our study 33% were among age group between 60-70 yrs. Coronary artery 
disease mortality among women gradually increases with age and increase in the 
risk of coronary artery disease is related to a higher incidence of hypertension, 
diabetes, obesity and dyslipidemia.
 From 1960 to 1995, the prevalence of CAD in adults increased from 3% to 10% in urban 
Indians and from 2% to 4% in rural Indians, with women having rates similar to men.
 In 1990, there were 783 000 deaths due to CAD in India and this is projected to double 
by the year 2015, primarily due to affluence and urbanization.
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 In the FHS, only 17% of women with typical angina developed an MI compared with 
44% of men.
 In the Coronary Artery Surgery Study (CASS), only 50% of women with typical angina 
had significant CAD compared with 83% of men.
 Grauer noted that data from the Framingham Heart Study revealed that for women, the 
initial manifestation of CAD is usually stable angina (47% in women compared to 26% in 
men).
 Women having an MI are more likely to present with atypical chest pain (midback pain) 
and atypical symptoms (indigestion, nausea, vomiting and dyspnea).
 In this study 88 out of (88%) 100 patients presented with chest pain. Other 
symptoms
 Nausea – 81%
 Vomiting – 61%
 In a study by MARRUGAT et al., (1998) showed that women are more likely 
to have symptoms such as nausea.
 Among Indian women, the presence of hypertension, diabetes, low levels of high density 
lipoprotein (HDL) and high levels of total cholesterol (TC), triglycerides (TG), low 
density lipoprotein (LDL), and Lp(a) are correlated with CAD
 At a given level of risk factors, compared to Americans, the CAD risk is 50% lower 
among southern Europeans but 50% higher among northern Europeans.
62
 The risk of CAD among Indians is even greater than in northern Europeans at any given 
level and/or combination of conventional risk factors
 In this study 45% presented with elevated Fasting Blood sugar Level.
 In this study 50% presented with elevated Postprandial glucose level.
 37% found to have elevated cholesterol levels
 57% found to have decreased HDL levels
 59% found to have high triglycerides levels
 40% found to have high LDL levels
 25% patients presented with High blood pressure.
 Hypertension confers a 4-fold risk of CAD in women versus a 3-fold one in men
 In the National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP 
III), diabetes is regarded as a CAD risk equivalent.
 Diabetes confers substantial increase relative risk of first, incident, and admission for MI 
for women with age-to-sex matched controls younger than age 65 yrs over 20 yrs follow 
up in COPENHAGEN CITY HEART STUDY.
 The INTERHEART study reported that the ratio of apolipoprotien (apo B to apo A-1) 
was an important risk marker for acute myocardial infarction. Higher levels were seen in 
South Asian cases.
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 The JAIPUR HEART WATCH (JHW) studies reported that there is a significant 
increase in total cholesterol, LDL cholesterol and triglycerides and a decline in HDL 
cholesterol is women and men at all age groups.
 GUPTA et al reported in Jaipur hypertension in females are high and JOSEPH et al
reported in Trivandrum reported SHT in females are high compared to male and increase 
the risk of CAD.
 HUXLEY AND COLLEAGUES found women with diabetes has 3.5 fold increase in 
cardiovascular mortality compared with non-diabetic women as well as their male 
counterpart.
 Cardiovascular disease is the most common complication of diabetes in women. Women 
with DM have CAD incidence similar to men, irrespective of age.
 The risk of CAD among diabetic subjects is remarkably higher compared to non diabetic 
subjects. The risk of death due to CAD in diabetic subjects with one prior myocardial 
infarction is similar to that sex in a non diabetic subjects with an earlier MI, while the risk 
is tri-placed in diabetic subjects with known MI. The life expectancy of diabetic patient is 
reduced by 30% compared to non diabetic subjects which translates to 8 year of loss of 
life in diabetic subjects. Further the protection in pre-menopausal women is abolished in 
diabetic premenstrual women.
 Physically active women have a 50% lower risk of CAD than sedentary women.
 The annual prevalence of obesity among U.S. adults age 20 and older has increased from 
19.4% in 1997 to 23.9% in 2002 (Centers for Disease Control and Prevention, 2003). For 
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the first six months of 2003, the prevalence of obesity among women was highest among 
non-Hispanic black women (38.7%), followed by Hispanic or Latino women (25.7%).
 A sedentary lifestyle is the most common risk factor for coronary disease in women, 
Grauer said, and as a group, women are less active then men. However, 30 to 45 minutes 
of walking three times a week could reduce the risk of MI by as much as 50%.
 In this study 89% reported sedentary habits. Major risk factors for CAD dependent on the 
demographic and societal transition are physical inactivity, excess dietary calories and fat 
intake, being overweight/obese, high blood pressure, diabetes, cholesterol levels, the 
metabolic syndrome and psychosocial stress.
 In this study 51% were found to have over weight
 In this study 23% were found to have obesity
 In this study 51% presented with >0.85 WHR.
 Obesity is linked to multiple cardiac risk factors like DM, SHT, Dyslipidemia.
In this study
 In our study prevalence of smoking among women was zero percent.
 A study LIAQUAT ALI CHEEMA et al, (Gender comparison of coronary risk factors 
and clinical presentation in Paskistani patients with coronary artery lesion).
 This showed that smoking was not a risk factor is females in the study population and 
diabetes mellitus and obesity were the common factors for CAD.
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 In a study by V.CHIAMVIMONSAT and L.STERNBERG (University of Toronto)
 Coronary artery disease is the leading cause of mortality in women, with incidence after 
menopause equal to that of men.
 Diabetes and post menopausal status are the strongest risk factors. 
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List of Findings
Age distribution Between 40-50yrs 17%
Between 50-60yrs 24%
Between 60-70yrs 33%
Between 70yrs 26%
BMI Healthy 26%
Overweight 51%
obese 23%
WHR >0.85 81%
<0.85 19%
Menstruation 7 patients were menstruating women
Sedentary habits 89%
H/O OCP intake 40%
Clinical symptoms Chest pain 88%
Nausea 81%
Vomiting 62%
Syncope 50%
Radiation of pain 31%
Palpitation , epigastric pain 29%
Clinical signs Lung Basal Crepitations 45%
Elevated JVP 23%
S3 16%
S4 24%
Wheeze 8%
Hypotension 10%
67
Type 2DM Fasting blood sugar 45%
Post prandial blood sugar 50%
Newly Detected 20%
Known Type 2DM 30%
SHT 25%
Lipid abnormalities High cholesterol 37%
Low HDL levels 57%
High LDL levels 40%
High triglycerides 59%
CRP Elevated CRP 71%
ECG abnormalities ST Elevation MI 80%
NON ST Elevation MI 10%
Unstable Angina 10%
Troponin in NSTEMI/UA Positive in 10 patients
Thrombolysed 21%
Risk AHA’S National Study In this Study
Overweight 41% 51%
Sedentary habits 40% 89%
Smoking 36% Nil
High Cholesterol 31% 37%
SHT 19% 25%
DM 7% 50%
TGL 1% 59%
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7. CONCLUSION
The following are the conclusions that could be inferred from this study on clinical spectrum and 
risk factors for CAD among female patients.
1. The most common presentation is chest pain.
2. The most common cardiovascular sign is Lung Basal Crepitations.
3. WHR associated with obesity and overweight increase the risk of Myocardial Infarction 
in female population
4. Most of the patients with Myocardial Infarction have dyslipidaemia.
5. Diabetes Mellitus clearly related to Myocardial Infarction during the premenopausal 
period. 
6. Hypertension is also associated with increased risk of Myocardial Infarction.
7. Sedentary habits are associated with increased risk of coronary artery disease.
8. Most common presentation is STEMI.
9. Among STEMI most common type of MI is ASMI.
10. OCP intake accounts for risk of being overweight and causes MI.
8. BIBLIOGRAPHY
1. Mosca L, Mochari H, Christian A, et al: National Study of Women’s Awareness, 
Perventive Action, Barriers to Cardiovascular Health. Circulation 2006;113:525-534.
2. Whitley L, Padmanabhan S, Hole D, Isles C. Should diabetes be considered a coronary 
artery disease equivalent? Results from 25 years of follow up in the Renfrew and Paisley 
Survey. Diabetes Care 2005;28:1588-1594.
3. Rennnert NJ, Charney P. Preventing cardiovascular disease in diabetes and glucose 
intolerance: evidence and implications for care. Prim Care 2003;30:569-592.
4. Weitman M, Cook S, Auinger P et al. Tobacco smoke exposure is associated with the 
metabolic syndrome in adolescents. Circulation 2005;112:862-869.
5. Barrett-Conner E, Giardina E, Gitt U, Tschoepe D. Women and heart disease:the role of 
diabetes and hyperglycemia. Arch Intern Med 2004;164:934-942.
6. Women’s Health Initiative Steering Committee. Effects of conjugated equine estrogen on 
postmenopausal women and hysterctomy: Women’s Health Initiative randomized 
controlled trial. JAMA 2004;291:1701-1712.
7. Sagie A. The natural history of borderline isolated systolic hypertension. N Engl J Med 
1993;329: 1912-1917.
8. Schaefer BM, Caracciolo V, Frishman WH, Charney P. Gender, ethinicity and genetics in 
cardiovascular disease: part II. Implications for pharmacotherapy. Heart Dis 2003;5:202-
214.
9. Expert Paenel on Detection, Evaluation, and treatment of High Blood Cholesterol in 
Adults (adult Treatment Panel III). JAMA 2001;285:2486-2497.
10. Walsh JME. Pignone M. Drug treatment if hyperlipiudemia in women. JAMA 
2004;291:2243-2252.
11. Prospective Diabetes Study Group. United Kingdom Prospective Diabetes Study 27: 
Plasma lipids and lipoproteins at diagnosis of NIDDM by age and sex. UK:Diabetes 
Care. 1997;20(11):1683-1687.
12. Schneider JG, Tompkins C, Blumenthal RS, Mora S. The metabolic syndrome in women. 
Cardiol Rev 2006;14:286-291.
13. Rennnert NJ, Charney P. Preventing cardiovascular disease in diabetes and glucose 
intolerance: evidence and implications for care. Prim Care 2003;30:569-592.
14. Yusuf S, Zhao F, Mehta SR, et al: Effects of clopidogrel in addition to aspirin in patients 
with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001, 345: 
494-502.
15. Charney P ed.Coronary artert disease in Women: prevention, Diagnosis and 
Management. Philadelphia: American College of Physicians:1999.
16. Wilson PE, Sullivan L, Kannel WB. Overweight and obesity as determinants of 
cardiovascular risk: the Framingham experience. Arch Intern Med 2002;162:1867-1872.
17. Winkleby MA, Robinson TN, Sundquist J, Kraemer HC. Ethnic variations in 
cardiovascular disease risk factors among children and young adults: findings from the 
third National Health and Nutrition Examination Survey,1988-1994. JAMA 
1999;281:1006-1013.
18. Franklin SS Pio Jr, Wrong ND, et al. Predictors of new onset diastolic and systolic 
hypertension: Framingham Heart Study. Circulation 2005;111:1121-1127.
19. Rosenberg RD, Aird WC: Vascular-bed-specific hemostasis and hypercoagulable states. 
N Engl J Med 1999;340:1555.
20. Alpert JS, et al: Definition of myocardial infarction- a global consensus document of The 
Joint ESC/ACC/AHA/WHF/WHO Task Force for the Redefinition of  Myocardial 
Infarction, 2007.
21. De Bacquer D, De Backer G, Kornitzer, Prevalence of ECG findings in large population 
based samples of men and women. Heart 2000;84:625-633.
22. Jaffe AS, Babuin L, Apple FS: Biomarkers in acute cardiac disease: The present and the 
future. J Am Coll Cardiol 2006; 48:1.
23. Giannitsis E, Katus HA: Biomarkers of necrosis for risk assessment and management of 
ST-elevation myocardial infarction. In: Morrow DA, ed. Cardiovascular Biomarkers: 
Pathophysiology and Disease Management, Totowa, NJ: Humana Press; 2006:119-128.
24. Antman EM, Anbe DT, Armstrong PW, et al: ACC/AHA guidelines for the management 
of patients with ST-elevation myocardial infarction: A report of the American College of 
Cardiology/American Heart Association Task Force on Practice Guidelines (Committee 
to Revise the 1999 Guidelines for the Management of patients with Acute Myocardial 
Infarction).
25. Sharkey SW, Lesser JR, Zenovich AG, et al.Acute and reversible cardiomyopathy 
provoked by stress in women from the United States. Circulation 2005;111(4):472-479.
26. Argulian E, Patel AD, Abramson JL, et al. Gender differences in short-term 
cardiovascular outcomes after percutaneous coronary interventions. Am I cardiol 
2006;98(1):48-53.
27. Haan Ck, Chiong JR, Coombs LP, et al. Comparsion of risk Profiles and outcomes in 
women versus men >75 years of age undergoing coronary artery bypass grafting. Am J 
cardiol 2003;91:1255-1258.
28. Albert CM, Chae CU, Grodstein F, et al. Prospective study of sudden cardiac death 
among women in the United States. Circulation 2003;107(16):2096-2101.
29. Tunstall-Pedoe H, Kuulasmaa K, Amouyel P, et al: Myocardial infarction and coronary 
deaths in the World Health Organization MONICA Project. Registration procedures, 
event rates, and case-fatality rates in 38 populations from 21 countries in four continents. 
Circulation 1994;90:583.
30. Cheitlin MD, McAllister HA, de Castro CM: Myocardial infarction without 
atherosclerosis. JAMA 231:951, 1975. Copyright 1975, American Medical Association.
31. Apple FS, Quist HE, Doyle PJ, et al: Plasma 99th percentile reference limits for caradiac 
troponin and creatine kinase MB mass for use with European Society of 
Cardiology/American College of Cardiology consensus recommendations. Clin Chem 
2003; 49:1331.
32. Sabatine MS, Morrow DA, Giugliano RP, et al: Association of hemoglobin levels with 
clinical outcomes in acute coronary syndromes. Circulation 2005;111:2042.
33. Moon JC, De Arenaza DP, Elkington AG, et al: The pathologic basis of Q-wave and non-
Q-wave myocardial infarction: A cardiovascular magnetic resonance study. J Am Coll 
Cardiol 2004; 44:554.
34. Cheitlin MD, Armstrong WF, Aurigemma GP, et al: ACC/AHA/ASE 2003 guideline 
update for the clinical application of echocardiography: A report of the American College 
of Cardiology/American Heart Association Task Force on Practice Guidelines 
(ACC/AHA/ASE Committee to update the 1997 Guidelines for the Clinical Application 
of Echocardiograpthy). American College of Cardiology web site, 2006.
35. Mosca L, Linfante A, Benjamin E, et al: National Study of Physician Awareness and 
Adherence to Cardiovascular Disease Prevention Guidelines. Circulation 2005;111:499-
510.
36. The Women’s Caucus, Working Group On Women’s Health of the Society of General 
Internal Medicine. Hypertension in Woman: what is really known? Ann Intern Med 
1991;115:287-293.
37. Christou D, Jones P, Jordan J, Diedrich A, Seals D. Women have lower tonic support of 
arterial blood pressure and less effective baroreflex buffering than men. Circulation 
2005;111:494-498.
38. Cooper WO, Hernandez-Diaz S, Arbogast PG. Major congenital malformations after first 
trimester exposure to ACE inhibitors. N Engl J Med 2006;354: 2443-2451.
39. Ogden CL, Carroll MD, Curtin LR, McDowell MA, Tabak CJ, Flegal KM. Prevalence of 
overweight and obesity in the United States, 1994-2004. JAMA 2004; 295:1549-1555.
40. Almdal T, Scharling H, Jensen J, Vestgaard H. The independence effect of type 2 
diabetes on ischemic heart disease, stroke and death. Arch Intern Med 2004; 164:1422-
1426.
41. Vaccarino V, Parsons L, Every N, et al. Impact of history of diabetes on hospital 
mortality in men and women with first acute myocardial infarction. Am J cardiol 
2000;85:1486-1489.
42. Persell S, Baker D. Aspirin use among adults with diabetes. Arch Intern Med 
2004;164:2492-2499.
43. Wlid R, Polycystic ovary syndrome: A risk for coronary artery disease? Am J Obstet 
Gynecol 2002;186(1):35-43.
44. Aoridonize T, Essah P, Iuorno M, Nestler J. Prevalence and characteristics of the 
metabolic syndrome in women with polycystic ovary syndrome. J clin Endocrinol Metab 
2005;90(4):1929-1935.
45. Yanoviski SZ, Yanoviski JA. Obesity. N Engl J Med 2002;346:591-602.  
46. Cole CR, Blackstone EH, Pashkow FJ, et al: Heart-rate recovery immediately after 
exercise as a predictor of mortality. N Engl J Med. 1999, 341: 1351-1357.
47. Antiplatelet Trialists’ Collaboration. Collaborative overview of randomized trials of 
antiplatelet therapy-I: Prevention of death, myocardial infarction, and stroke by 
prolonged antiplatelet therapy in various categories of patients. BMJ. 1994, 308: 81-106.
48. Roiron C, Sanchez P, Bouzamondo A, et al: Drug-eluting stents: An updated meta-
analysis of randomized controlled trials. Heart. 2006, 92: 641-649.
49. Yusuf S, Sleight P, Pogue J, et al: Effects of an angiotensin-converting-enzyme inhibitor, 
ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention 
Evaluation Study Investigators. N Engl J Med. 2000, 342: 145-153.
CLINICAL  FEATURES
SYMPTOMS
HT WT BMI N VO S R DY O JVP S3 S4CREPT WHZ SHT              LIPID SMO ALC MENS SED ECG ECHO TRO THR WHR OCP CRP
S.NO F PP TC TG LDL HDL
1 40 24991 142 63 31.2 Y N N N N Y Y N N Y N 130/90 140 196 222 300 170 168 N N N Y Y N ND Y Y Y Y
2 45 24951 139 49 28.4 Y Y N Y N N N N N N N 160/98 90 130 160 130 112 38 N N Y N Y N ND Y Y Y N
3 43 24812 141 70 35.2 Y N N N N N N N N N N 120/70 170 220 202 186 168 37 N N Y N Y N ND Y Y Y N
4 43 26244 153 69 29.5 N N N Y N Y Y Y N Y N 150/90 80 180 142 130 112 32 N N Y Y Y Y ND Y Y Y N
5 69 26360 137 46 24.5 Y N N N N N N N N N N 160/90 76 120 140 130 107 33 N N N N Y Y ND Y Y N N
6 65 27745 152 45 19.5 Y N N Y N N N N N N N 120/70 250 160 200 140 98 30 N N N Y Y Y ND Y N N N
7 63 27777 138 66 34.7 Y N N Y N N N N N N N 130/80 180 330 220 340 170 64 N N N Y Y Y ND Y Y N Y
8 65 31327 142 57 28.3 Y Y Y Y N N N N N N N 140/80 150 140 180 120 98 32 N N N Y Y Y ND Y Y N N
9 56 31643 141 70 35.2 Y N N Y N Y N N N N N 190/90 90 126 140 180 108 34 N N N Y Y Y ND Y Y N N
10 65 32160 142 68 33.8 Y N Y N N N N N N N N 170/98 90 120 200 176 118 36 N N N Y Y Y ND Y Y N N
11 60 32781 140 53 27 Y N Y N N Y N N N Y N 190/100 86 132 198 330 162 68 N N N Y Y Y ND Y Y N Y
12 55 34192 144 59 25.5 Y Y Y N N N N N N N N 130/80 76 118 198 300 167 67 N N N Y Y Y ND Y Y N Y
13 55 34229 148 54 24.7 Y Y N Y N N N N N N N 120/80 90 112 248 330 161 66 N N N Y Y Y ND Y Y N Y
14 70 35771 143 79 38.6 Y Y Y Y N N N N N N N 110/70 80 122 270 350 180 64 N N N Y Y Y ND Y Y N Y
15 70 36237 147 55 25.5 Y Y N N N N N N N N N 110/70 76 132 208 300 163 67 N N N Y Y Y ND N Y N Y
16 55 34181 150 63 28 Y Y Y Y N Y Y Y N Y N 90/70 79 129 200 202 162 68 N N N Y Y Y ND N Y Y Y
17 80 38457 141 54 27.1 Y Y Y Y Y Y Y Y Y Y Y 80/60 90 330 200 408 165 72 N N N Y Y Y ND N Y N Y
18 80 38512 151 47 20.6 Y Y Y Y Y Y Y Y Y Y Y 90/70 190 330 190 112 122 36 N N N Y Y Y ND N N N N
19 75 38584 143 54 26.4 N N N N N N N N N N N 110/70 180 340 180 100 126 38 N N N Y Y Y ND N Y N N
20 75 397773 146 62 29.1 N N N N N N N N N N N 120/80 110 140 208 300 171 66 N N N Y Y Y ND N Y N Y
21 62 40070 155 56 23.3 Y Y N N N N N N N N N 130/80 96 126 220 316 182 69 N N N Y Y Y ND N N N Y
22 70 40310 141 66 33.2 Y Y N N N N N N N N N 120/80 110 130 280 314 201 64 N N N Y Y Y ND N Y Y Y
23 85 44657 139 58 30 N N N Y N N N N N N N 120/80 80 126 180 300 207 66 N N N Y Y Y ND N Y N Y
24 60 45053 152 54 23.4 Y Y Y Y Y N N N N N N 130/80 90 130 174 400 162 64 N N N Y Y Y ND N Y N Y
25 74 44863 143 70 34.2 N Y Y Y N N N N N N N 120/80 78 138 200 110 163 38 N N N Y Y Y ND N Y Y N
26 40 45095 151 53 23.2 Y Y N N N N N N N N N 110/80 88 128 210 110 126 38 N N N Y Y Y ND N Y N N
27 80 46086 140 56 28.6 Y Y Y N N N N N N N N 120/80 186 330 110 304 161 64 N N N Y Y Y ND N Y Y Y
28 75 45206 144 55 26.5 Y N N Y N N N N N N N 144/90 190 320 188 318/ 182 62 N N N Y Y Y ND N Y N Y
29 82 46041 140 67 34.1 Y Y Y N N Y N Y N Y N 170/80 180 330 200 380 196 14 N N N Y Y Y ND N Y N Y
30 82 47364 153 71 30.3 Y Y S N Y Y Y Y Y Y N 200/100 84 128 208 110 125 36 N N N Y Y Y ND N Y N N
31 50 48760 148 58 26.5 Y N N N N N N N N N Y 110/80 74 128 210 333 196 66 N N N Y Y Y ND N Y N Y
32 65 48719 145 55 26.2 Y N Y N N N N N N N N 130/80 70 130 280 400 190 69 N N N Y Y Y ND N Y Y Y
33 70 48852 153 65 27.8 Y Y Y Y Y Y N N N Y N 90/70 90 130 200 408 182 69 N N N Y Y Y ND N Y Y Y
34 55 49212 147 58 26.8 Y Y Y Y Y N N N N N N 150/90 78 126 114 340 172 67 N N N Y Y Y ND N Y N Y
35 85 1760 152 61 29.4 Y Y N Y Y Y N N N Y N 160/90 80 120 200 300 193 63 N N N Y Y Y ND N Y N Y
36 72 2968 162 50 19 Y N N Y N N N N N N N 90/70 190 300 202 108 122 34 N N N N Y Y ND N Y N N
37 65 2970 157 60 26.3 Y N Y N N N N N N N N 120/90 148 294 198 300 112 63 N N N N Y Y ND N Y N Y
38 68 4415 142 49 24.3 Y Y Y N N N N N N N N 160/80 136 196 228 312 114 63 N N N N Y Y ND N N N Y
39 65 4493 142 50 22.5 Y Y Y Y N N N N N N N 110/90 148 222 180 302 128 65 N N N N Y Y ND N Y Y Y
40 48 5805 152 54 23.3 Y Y Y N N N N N N N N 130/80 200 404 172 376 193 67 N N N N Y Y ND N N Y Y
41 50 5977 154 51 21.5 Y Y Y Y N N N N N Y N 120/80 110 130 148 140 116 34 N N N N Y Y ND N N Y N
42 55 7064 148 58 26.4 N Y Y N N N N N N Y N 120/80 96 118 222 132 114 34 N N N N Y Y ND N Y Y N
43 79 7125 150 65 28.8 Y Y N Y Y N N N N Y N 130/100 100 122 202 118 112 34 N N N N Y Y ND N Y N N
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CLINICAL  FEATURES
HT WT BMI N VO S R DY O JVP S3 S4CREPT WHZ SHT SMO ALC MENS SED ECG ECHO TRO THR WHR OCP CRP
F PP TC TG LDL HDL
44 42 8454 149 63 28 N Y Y Y Y N N N N Y N 130/80 186 336 170 300 142 66 N N Y Y Y Y ND N Y Y Y
45 65 8589 145 55 26 Y Y Y Y Y N N N N Y N 160/80 172 316 156 312 147 66 N N Y Y Y Y ND N Y N Y
46 66 8606 153 65 28 Y Y N Y N N N N N Y N 130/80 90 110 156 302 152 64 N N Y Y Y Y ND N Y N Y
47 65 11245 150 63 28 Y Y Y N N Y Y Y N N N 180/100 78 128 148 376 196 64 N N Y Y Y Y ND N Y N Y
48 46 11709 147 58 27 Y Y N N N Y N Y N N N 130/90 90 110 202 140 102 34 N N N Y Y Y ND N Y Y Y
49 67 11811 153 67 29 N N N N N Y N N N N N 190/100 70 110 220 132 108 34 N N N Y Y Y ND N Y N Y
50 63 12668 144 48 23 N N N Y N N Y N N Y Y 130/80 202 336 200 118 106 38 N N N Y Y Y ND N Y N Y
51 70 15613 149 56 25 N N N Y N Y N Y N Y N 160/90 176 286 244 306 98 39 N N N Y Y Y ND N N N Y
52 42 15797 150 61 27 N N Y N Y N Y N N Y N 200/100 174 296 202 318 94 37 N N N Y Y Y ND N Y Y Y
53 85 15856 152 68 29 Y Y N N N Y N N N Y N 200/100 166 316 220 122 112 35 N N N Y Y Y ND N Y N Y
54 48 17168 149 49 22 N Y N Y N N Y N N N N 120/80 174 348 200 116 116 35 N N N Y Y Y ND N N Y Y
55 65 16830 147 52 29 N Y Y N Y N N N Y N N 190/100 114 388 244 116 117 35 N N N Y Y Y ND N Y N Y
56 80 17314 146 59 28 Y Y Y N N N N N N N N 120/80 110 306 202 108 104 34 N N N Y Y Y ND N Y N N
57 79 17809 162 50 19 Y Y N Y N N N N N N N 160/80 90 228 198 208 104 36 N N N Y Y Y ND N N N N
58 65 14301 143 47 23 Y Y N Y Y N N N N Y N 130/80 76 110 148 300 106 30 N N N Y Y Y ND N N N N
59 91 18951 158 59 24 Y Y N N Y Y N Y N Y N 120/80 202 126 178 316 111 28 N N N Y Y Y ND N N N N
60 55 19020 153 66 28 N N Y N Y Y N Y Y Y N 110/80 90 336 178 380 144 66 N N N Y Y Y ND N Y Y Y
61 72 19032 147 63 28 Y Y N N Y N Y Y Y Y N 110/70 222 110 179 378 144 68 N N N Y Y Y ND N Y N Y
62 55 21187 151 60 26 Y N Y Y N N Y Y Y Y Y 90/60 200 401 190 306 117 69 N N Y Y Y Y ND N N Y Y
63 60 22478 147 61 28 Y Y Y N N Y N N Y Y N 90/60 174 290 190 308 121 72 N N Y Y Y Y ND N N Y Y
64 58 22486 153 58 25 Y Y N Y N Y N N N Y Y 80/80 180 298 190 310 126 28 N N Y Y Y Y ND N Y Y Y
65 72 24777 149 62 28 Y N N Y N Y Y N N N N 110/70 78 398 222 130 126 32 N N Y Y Y Y ND N Y N Y
66 70 75290 145 69 33 Y N N N N Y Y N N N N 110/70 70 128 240 130 128 32 N N N Y Y Y ND N Y N Y
67 72 75648 152 55 24 Y N N N N Y Y N Y N N 120/80 90 172 200 100 126 30 N N N Y Y Y ND N N N Y
68 70 662 153 70 30 Y N Y N Y Y Y N Y Y N 110/70 78 128 202 300 126 28 N N N Y Y Y ND N Y N Y
69 60 1036 149 57 26 Y Y Y N N Y Y N Y Y N 90/60 80 132 180 117 129 26 N N N Y Y Y ND N Y Y Y
70 59 3009 149 57 23 Y Y N N N Y Y N Y Y N 100/70 90 140 188 330 155 65 N N N Y Y Y ND N N Y Y
71 45 3214 147 63 29 Y Y N N N N Y N Y Y N 130/80 186 333 176 340 145 65 N N N Y Y Y ND N Y Y Y
72 60 3258 150 70 31 Y N N N N N N N N Y N 110/70 176 380 176 370 147 67 N N Y Y Y Y ND N Y Y Y
73 60 3282 148 54 25 Y N N N N N N N N N N 120/80 200 342 190 374 212 69 N N Y Y Y Y ND N N N Y
74 75 4599 151 64 29 Y N N N N N N N Y N N 120/80 192 400 190 110 118 26 N N Y Y Y Y ND N Y N N
75 75 4679 150 63 28 Y N N N N N N N Y Y N 110/80 92 120 176 110 116 28 N N Y Y Y Y ND N Y N Y
76 85 3955 147 58 27 Y N N N Y N N N Y Y N 130/80 112 140 220 116 104 32 N N Y Y Y Y ND N Y Y Y
77 50 4707 151 62 27 Y N N N Y N N N Y Y N 200/100 84 150 220 116 102 32 N N N Y Y Y ND N Y Y Y
78 45 4593 154 51 22 Y N N N Y N N N Y Y N 110/80 120 190 300 122 98 32 N N N Y Y Y ND N N Y Y
79 70 4799 147 63 29 Y N N N N N N N Y Y N 120/80 122 160 245 110 96 34 N N N Y Y Y ND N Y Y Y
80 60 6013 151 60 26 Y Y Y Y Y N N N N Y N 130/80 95 130 165 110 90 33 N N N Y Y Y ND N Y Y Y
81 57 7282 144 59 29 Y Y Y N N N N N N Y N 170/100 110 180 220 330 147 29 N N N Y Y Y Y N Y Y Y
82 65 7246 148 54 25 Y Y Y N N N N N N Y N 150/90 160 224 200 314 149 31 N N N Y Y Y Y N Y Y Y
83 75 10077 141 70 35 Y Y Y Y N N N N N Y N 190/100 220 336 222 400 100 72 N N N Y Y Y Y N Y N Y
84 60 10239 150 63 28 Y Y N N N N N N N N N 120/80 110 180 180 130 106 29 N N N Y Y Y Y Y Y Y N
85 45 10142 139 58 80 Y Y N N N Y Y N N N N 120/80 146 228 186 120 109 29 N N Y Y Y Y Y Y Y Y N
LIPID
Y
Y
Y
N
Y
Y
Y
Y
N
Y
N
N
Y
Y
Y
Y
SYMPTOMS
CP
Y
Y
Y
Y
Y
Y
Y
Y
DM
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
CLINICAL  FEATURES
SYMPTOMS
HT WT BMI N VO S R DY O JVP S3 S4CREPT WHZ SHT SMO ALC MENS SED ECG ECHO TRO THR WHR OCP CRP
F PP TC TG LDL HDL
86 70 13073 182 54 24 Y Y Y Y N N N N N N N 120/80 130 196 146 150 104 31 N N N Y Y Y Y Y N N Y
87 64 14757 143 70 34 Y Y Y Y Y Y Y Y Y Y Y 130/78 200 332 200 314 155 64 N N N Y Y Y Y Y Y N Y
88 80 1486 140 56 29 Y Y Y Y Y N Y N N N N 110/70 108 138 184 129 113 29 N N N Y Y Y Y Y Y N Y
89 48 18521 144 55 27 N N Y N N N N N N N N 130/80 107 127 180 107 119 27 N N N Y Y Y Y Y Y Y Y
90 54 18872 140 67 34 N N N Y N N Y N N N N 130/78 188 290 222 300 158 62 N N N Y Y Y Y Y Y Y Y
91 60 22088 141 70 35 Y Y N N Y N N N N N N 124/70 144 212 177 122 117 34 N N N Y Y Y N N Y Y Y
92 70 22765 153 71 30 N N Y Y N Y N Y Y N N 170/100 144 288 198 180 117 34 N N N Y Y Y N N Y N Y
93 65 12636 140 67 34 Y Y Y N N N N N N N N 110/70 166 300 202 301 104 36 N N N Y Y Y N N Y N Y
94 54 23229 140 56 29 Y Y Y Y Y N N N N Y N 100/80 110 140 212 308 156 64 N N N Y Y Y N N Y Y Y
95 60 27411 151 53 23 N Y Y N N N N N N Y N 110/80 90 110 300 412 106 66 N N N Y Y Y N N N N N
96 65 2679 152 54 23 Y Y Y Y Y Y N Y Y Y Y 90/70 218 412 132 228 121 34 N N N Y Y Y N N N N N
97 75 27811 179 58 30 Y Y Y Y Y N N N N N N 110/80 110 132 170 140 128 34 N N N Y Y Y N N Y N N
98 64 28002 147 55 26 Y Y Y Y Y N N N N N N 120/80 106 126 110 156 121 36 N N N Y Y Y N N Y Y N
99 55 30942 138 66 35 N Y Y N N N N N N N N 120/80 98 116 94 122 111 38 N N N Y Y Y N N Y Y N
100 70 26719 141 70 35 Y Y Y Y Y Y N N N N N 120/80 90 110 90 130 113 36 N N N Y Y Y N N Y N Y
CP -Chest Pain
N - Nausea
V - Vomiting
S - Syncope
O - Others
Crept - Crepitation
WHZ - Wheeze
SMO - Smoking
ALC - Alcohol
MENS - Menstruation
SED - Sedentary Habits
TRO - Troponin
THR - Thrombolysed
WHR - Waist Hip Ratio
OCP - Oral Contraceptive Pills
ND - Not Done
LIPID
Y
N
Y
Y
Y
N
Y
Y
Y
N
Y
Y
Y
Y
Y
CP DM
INFORMED CONSENT
Department of General Medicine
Coimbatore Medical College, Coimbatore
Principal Investigator : Dr. E.ARUL ANANDHAN
Research guide :  Dr. S.USHA
Organization :  Department of General Medicine
Informed Consent : I have been invited to participate in research project titled
'CORONARY ARTERY DISEASE IN FEMALES'
I understand it will involve answering a set of questionnaire, undergo physical 
examination and basic investigations. 
Also I give consent to utilize my personal details for study purpose and can be 
contacted if necessary. 
I am aware that I have the right to withdraw at any time which will not affect my 
medical care. 
Name of participant :
Signature :
Date :
